Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight

This study aimed to identify the optimal dose of the endothelin‐1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium retention, as manifested by increase in bodyweight. Data from the RADAR‐JAPAN studies were used, evaluating the effect of 0.75 or 1.25 mg/d...

Descripción completa

Detalles Bibliográficos
Autores principales: Koomen, Jeroen V., Stevens, Jasper, Mostafa, Nael M., Parving, Hans‐Henrik, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055665/
https://www.ncbi.nlm.nih.gov/pubmed/29603851
http://dx.doi.org/10.1111/dom.13312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055665/
https://www.ncbi.nlm.nih.gov/pubmed/29603851
http://dx.doi.org/10.1111/dom.13312

Ejemplares similares